Sarcoma Adjuvant treatment Maintenance chemotherapy Pathological stage Grade 3, 4, or 5 Neoadjuvant treatment Carcinoma Maintenance chemotherapy Cure Adenocarcinoma Tyrosine kinase inhibitors (TKIs) leukemia Partial Remission Antibody Drug Conjugate (ADCs) Surgical margin Minimal residual disease (MRD) Complete remission Monoclonal antibody Clinical stage Active surveillance TNM staging system Complementary therapy Recurrence Palliation Tumor Definitive treatment Chemotherapy CTACAE Checkpoint inhibitor ECOG performance status performance status Refractory Relapse Cellular therapy Sarcoma Adjuvant treatment Maintenance chemotherapy Pathological stage Grade 3, 4, or 5 Neoadjuvant treatment Carcinoma Maintenance chemotherapy Cure Adenocarcinoma Tyrosine kinase inhibitors (TKIs) leukemia Partial Remission Antibody Drug Conjugate (ADCs) Surgical margin Minimal residual disease (MRD) Complete remission Monoclonal antibody Clinical stage Active surveillance TNM staging system Complementary therapy Recurrence Palliation Tumor Definitive treatment Chemotherapy CTACAE Checkpoint inhibitor ECOG performance status performance status Refractory Relapse Cellular therapy
(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
Sarcoma
Adjuvant treatment
Maintenance chemotherapy
Pathological stage
Grade 3, 4, or 5
Neoadjuvant treatment
Carcinoma
Maintenance chemotherapy
Cure
Adenocarcinoma
Tyrosine kinase inhibitors (TKIs)
leukemia
Partial Remission
Antibody Drug Conjugate (ADCs)
Surgical margin
Minimal residual disease (MRD)
Complete remission
Monoclonal antibody
Clinical stage
Active surveillance
TNM staging system
Complementary therapy
Recurrence
Palliation
Tumor
Definitive treatment
Chemotherapy
CTACAE
Checkpoint inhibitor
ECOG performance status
performance status
Refractory
Relapse
Cellular therapy